Provided by Tiger Fintech (Singapore) Pte. Ltd.

OCUMENSION-B

10.330
+0.1801.77%
Volume:3.54M
Turnover:36.31M
Market Cap:8.41B
PE:-24.10
High:10.410
Open:10.150
Low:10.020
Close:10.150
Loading ...

Ocumension Therapeutics' (HKG:1477) Shift From Loss To Profit

Simply Wall St.
·
31 Jul

Sino Biopharm (01177) Surges Over 5% on $500M Acquisition of Liannovo Pharma with $4B Licensing Portfolio

Market Watcher
·
16 Jul

Sino Biopharmaceutical Surges 5% in Early Trading with $500 Million Acquisition of Shanghai Laixin Pharmaceuticals

Market Watcher
·
16 Jul

Sino Biopharm (01177) Surges Over 5% at Open with $500M Lixin Pharma Acquisition, Total Licensing Deals Near $4B

Stock Track
·
16 Jul

Ocumension Therapeutics (HKG:1477 shareholders incur further losses as stock declines 6.0% this week, taking five-year losses to 74%

Simply Wall St.
·
10 Jul

Ocumension Therapeutics Announces New Appointments to Nomination Committee Ahead of Governance Code Changes

Reuters
·
01 Jul

Ocumension Therapeutics Announces Management Changes with New Board Appointments

Reuters
·
24 Jun

Ocumension Therapeutics Conducted Annual General Meeting

Reuters
·
19 Jun

Ocumension Therapeutics Gets China Nod for Phase 3 Trial of Presbyopia Drug

MT Newswires Live
·
11 Jun

Ocumension Therapeutics Receives Approval to Initiate Phase III Clinical Trial for Presbyopia Treatment in China

Reuters
·
10 Jun

Ocumension Therapeutics Gets Nod for Real World Study of Intravitreal Implant in China

MT Newswires Live
·
14 May

Ocumension Therapeutics Announces Approval of OT-703 for Real World Study in Hainan Boao

Reuters
·
13 May

Ocumension Therapeutics' 2024 Loss Narrows

MT Newswires Live
·
02 Apr

When Will Ocumension Therapeutics (HKG:1477) Turn A Profit?

Simply Wall St.
·
27 Feb

Ocumension Therapeutics Expects Higher 2024 Revenue

MT Newswires Live
·
13 Feb

BRIEF-Ocumension Therapeutics Sees Revenue RMB408 To RMB420 Million For Year

Reuters
·
12 Feb